Dermata Therapeutics, Inc.

corporate_fare Company Profile

Dermata Therapeutics, Inc.

DRMA·NASDAQ·Life Sciences·CIK 0001853816

Dermata Therapeutics, Inc. is a scientific leader in skincare, dedicated to the development and commercialization of products addressing common and underserved skin conditions. The Company was initially founded to research and develop prescription products. Its lead asset, XYNGARI (also known as DMT310), was studied in clinical trials for moderate-to-severe acne. In March 2025, Dermata announced statistically significant results from its Phase 3 STAR-1 clinical trial of XYNGARI, which demonstrated statistically significant results across all three co-primary endpoints at weeks 4, 8, and 12 when compared with placebo. Following this trial, in September 2025, management, with board support, shifted strategy to developing and distributing direct-to-consumer (DTC) and business-to-business (B2B) skincare products. This strategic repositioning aims to accelerate commercialization, reduce regulatory burden, and decrease development expenses by leveraging the Company's dermatology knowledge to create effective and safe skincare products available without a prescription.

Dermata Therapeutics, Inc. (NASDAQ:DRMA) is a publicly traded company in the Life Sciences sector. Wiseek monitors DRMA SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

CFO Kyri K. Van Hoose Discloses 9% Stake After $750K Private Placement Purchase (2026-06-01)
Dermata Therapeutics Finalizes $100M Universal Shelf Offering Amid Going Concern (2026-05-29)
Shareholders Approve Highly Dilutive Warrant Issuances and Repricing (2026-05-27)
Dermata Therapeutics Files $100M Universal Shelf Registration Amid Going Concern Warning (2026-05-22)
Q1 Results Show Persistent Going Concern, New Lawsuit Threatens Skincare Launch, Dilutive Financing Continues (2026-05-13)

Financial Snapshot

Fiscal year ended December 31, 2025

Net Income

-$7.56M

Diluted EPS

-$8.16

Op. Cash Flow

-$7.76M

Operating Income

-$7.77M

Cash & Equivalents

$7.52M

Debt / Equity

0.00×

Shares Outstanding

2.66M sh

Source: 10-K · filed 2026-03-26 · accession 0001493152-26-012992

Browse all tickers starting with D →

show_chartPrice Chart

Loading chart...

feed DRMA - Latest Insights

Filing Type

Date Range

DRMA

Jun 01, 2026, 4:34 PM EDT

Filing Type: SCHEDULE 13D

Importance Score:

CFO Kyri K. Van Hoose Discloses 9% Stake After $750K Private Placement Purchase

Price at Filing: $1.36

Real-time Price: $1.19

Change: -$0.174 (-13%)

Market Cap: $4.746M

Sentiment: Positive

View Wiseek Article

DRMA

May 29, 2026, 5:25 PM EDT

Filing Type: 424B3

Importance Score:

Dermata Therapeutics Finalizes $100M Universal Shelf Offering Amid Going Concern

Price at Filing: $1.29

Real-time Price: $1.19

Change: -$0.100 (-8%)

Market Cap: $4.746M

Sentiment: Negative

View Wiseek Article

DRMA

May 27, 2026, 4:57 PM EDT

Filing Type: 8-K

Importance Score:

Shareholders Approve Highly Dilutive Warrant Issuances and Repricing

Price at Filing: $1.30

Real-time Price: $1.19

Change: -$0.110 (-8%)

Market Cap: $4.746M

Sentiment: Negative

View Wiseek Article

DRMA

May 22, 2026, 5:15 PM EDT

Filing Type: S-3/A

Importance Score:

Dermata Therapeutics Files $100M Universal Shelf Registration Amid Going Concern Warning

Price at Filing: $1.26

Real-time Price: $1.19

Change: -$0.070 (-6%)

Market Cap: $4.746M

Sentiment: Negative

View Wiseek Article

DRMA

May 13, 2026, 4:08 PM EDT

Filing Type: 10-Q

Importance Score:

Q1 Results Show Persistent Going Concern, New Lawsuit Threatens Skincare Launch, Dilutive Financing Continues

Price at Filing: $1.16

Real-time Price: $1.19

Change: +$0.030 (+3%)

Market Cap: $4.746M

Sentiment: Negative

View Wiseek Article

DRMA

May 13, 2026, 4:05 PM EDT

Filing Type: 8-K

Importance Score:

Dermata Therapeutics Reports Q1 Results, Secures $2M via ATM, and Advances DTC Skincare Launch

Price at Filing: $1.16

Real-time Price: $1.19

Change: +$0.030 (+3%)

Market Cap: $4.746M

Sentiment: Neutral

View Wiseek Article

DRMA

May 13, 2026, 4:05 PM EDT

Source: Access Newswire

Importance Score:

Dermata Therapeutics Raises $2M via ATM, Extends Cash Runway to Q1 2027

Price at Filing: $1.21

Real-time Price: $1.19

Change: -$0.020 (-2%)

Market Cap: $4.746M

Sentiment: Positive

View Wiseek Article

DRMA

Apr 17, 2026, 5:03 PM EDT

Filing Type: DEFA14A

Importance Score:

Shareholders to Vote on Significant Dilution and Warrant Repricing Amidst Going Concern

Price at Filing: $1.38

Real-time Price: $1.19

Change: -$0.190 (-14%)

Market Cap: $4.746M

Sentiment: Negative

View Wiseek Article

DRMA

Apr 17, 2026, 5:01 PM EDT

Filing Type: DEF 14A

Importance Score:

Shareholders to Vote on Highly Dilutive Warrant Issuance, Repricing, and Equity Plan Expansion

Price at Filing: $1.38

Real-time Price: $1.19

Change: -$0.190 (-14%)

Market Cap: $4.746M

Sentiment: Negative

View Wiseek Article

DRMA

Apr 02, 2026, 8:30 AM EDT

Source: Access Newswire

Importance Score:

Dermata Secures Australian Patent Acceptance for Topical Dermal Filler Delivery System

Price at Filing: $1.20

Real-time Price: $1.19

Change: -$0.010 (-0.83%)

Market Cap: $4.746M

Sentiment: Positive

View Wiseek Article

DRMA

Mar 26, 2026, 5:25 PM EDT

Source: Wiseek News

Importance Score:

Dermata Therapeutics Narrows Annual Net Loss to $7.56M, Confirms Strategic Pivot

Price at Filing: $1.38

Real-time Price: $1.19

Change: -$0.1893 (-14%)

Market Cap: $4.746M

Sentiment: Neutral

View Wiseek Article

DRMA

Mar 26, 2026, 5:17 PM EDT

Filing Type: 10-K

Importance Score:

Dermata Therapeutics Faces Going Concern Amidst Massive Dilutive Financings and Strategic Pivot

Price at Filing: $1.36

Real-time Price: $1.19

Change: -$0.170 (-13%)

Market Cap: $4.746M

Sentiment: Negative

View Wiseek Article

DRMA

Mar 26, 2026, 5:15 PM EDT

Source: Access Newswire

Importance Score:

Dermata Raises $15.4M, Launches 'Tome' Skincare Brand in Strategic DTC Pivot

Price at Filing: $1.35

Real-time Price: $1.19

Change: -$0.160 (-12%)

Market Cap: $4.746M

Sentiment: Positive

View Wiseek Article

DRMA

Feb 25, 2026, 4:05 PM EST

Filing Type: 8-K

Importance Score:

Director Mary Fisher Resigns from Dermata Therapeutics Board Due to Employer Acquisition

Price at Filing: $1.22

Real-time Price: $1.19

Change: -$0.030 (-2%)

Market Cap: $4.746M

Sentiment: Neutral

View Wiseek Article

DRMA

Feb 03, 2026, 4:05 PM EST

Filing Type: 8-K

Importance Score:

Dermata Therapeutics Changes Independent Auditor, Appointing Former Firm CBIZ CPAs

Price at Filing: $1.90

Real-time Price: $1.19

Change: -$0.7086 (-37%)

Market Cap: $4.746M

Sentiment: Neutral

View Wiseek Article

DRMA

Jan 29, 2026, 5:12 PM EST

Filing Type: 424B3

Importance Score:

Dermata Therapeutics Finalizes Resale Prospectus for 6.2M Shares and Warrants, Securing Potential $8.6M Capital

Price at Filing: $2.86

Real-time Price: $1.19

Change: -$1.67 (-58%)

Market Cap: $4.746M

Sentiment: Neutral

View Wiseek Article

DRMA

Jan 27, 2026, 8:00 AM EST

Filing Type: 424B5

Importance Score:

Dermata Therapeutics Updates At-The-Market Offering Capacity to $705,000

Price at Filing: $3.02

Real-time Price: $1.19

Change: -$1.83 (-61%)

Market Cap: $4.746M

Sentiment: Neutral

View Wiseek Article

DRMA

Jan 08, 2026, 4:05 PM EST

Filing Type: SCHEDULE 13D/A

Importance Score:

Dermata Therapeutics CEO Gerald Proehl Invests $1.25M in Private Placement, Increasing Stake to 24.7%

Price at Filing: $2.14

Real-time Price: $1.19

Change: -$0.950 (-44%)

Market Cap: $4.746M

Sentiment: Positive

View Wiseek Article

corporate_fare Company Profile